Key Developments: Accuray Inc (ARAY.O)

ARAY.O on Nasdaq

9.00USD
20 Apr 2015
Change (% chg)

-- (--)
Prev Close
$9.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,246,725
52-wk High
$10.01
52-wk Low
$5.99

Search Stocks

Latest Key Developments (Source: Significant Developments)

Accuray and Christie InnoMed sign exclusive sales agent agreements for radiation therapy systems in Canada
Thursday, 5 Mar 2015 08:30am EST 

Accuray Inc:Enters into sales agent agreements involving the CyberKnife(®) and TomoTherapy(®) System product portfolios in Canada.Under the terms of these agreements, Christie InnoMed will be the exclusive sales agent for Accuray products in this region.  Full Article

Accuray Inc reaffirms FY 2015 guidance
Tuesday, 27 Jan 2015 04:01pm EST 

Accuray Inc:Reaffirms its financial guidance for FY 2015 and expect total revenue of $390.0 million to $410.0 million and adjusted EBITDA of $18.0 million to $27.0 million.FY 2015 revenue of $393 million - Thomson Reuters I/B/E/S.  Full Article

Accuray Inc reaffirms FY 2015 guidance
Wednesday, 29 Oct 2014 04:04pm EDT 

Accuray Inc:Reaffirms its financial guidance for FY 2015 on total revenue of $390 million to $410 million and adjusted EBITDA of $18 million to $27 million.FY 2015 revenue of $402 million - Thomson Reuters I/B/E/S.  Full Article

Accuray signs radiation therapy solutions contract with Premier Inc
Tuesday, 9 Sep 2014 08:35am EDT 

Accuray Inc:Says it has been awarded a new, three-year group purchasing agreement with Premier, Inc., covering the CyberKnife M6 and TomoTherapy HDA product portfolios.Says the Accuray and Premier partnership brings together two companies committed to driving improved patient care through meaningful technical innovation.  Full Article

Accuray Inc gives FY 2015 guidance in line with analysts' estimates
Thursday, 21 Aug 2014 04:02pm EDT 

Accuray Inc:Expects FY 2015 revenues to be in the range of $390 million to $410 million.Expects FY 2015 adjusted EBITDA to be in the range of $18 million to $27 million.FY 2015 revenue of $398 million and EBITDA of $27 million - Thomson Reuters I/B/E/S.  Full Article

Accuray Inc signs three-year contract with Amerinet
Tuesday, 6 May 2014 08:30am EDT 

Accuray Inc:Signed new three-year contract with Amerinet on CyberKnife and TomoTherapy product portfolio.Under agreement, Accuray Inc's precise, leading-edge technologies, delivering full range of radiation therapy and radiosurgery treatments, are immediately available to hospitals that Amerinet serves.  Full Article

Accuray signs three-year contract With Novation
Wednesday, 30 Apr 2014 04:07pm EDT 

Accuray Inc:Signed a new three-year contract with Novation on the CyberKnife M6 and TomoTherapy H product portfolio.Under the new agreement, Accuray's precise, technologies, delivering the full range of radiation therapy and radiosurgery treatments, are now available for the hospital members that Novation serves.  Full Article

Accuray raises FY 2014 revenue guidance
Wednesday, 30 Apr 2014 04:02pm EDT 

Accuray Inc:Updates financial guidance of total revenue for FY 2014 to range of $355 mln $365 mln.This compares to the previous financial guidance of total revenue in the range of $340 mln $350 mln which was provided on Jan. 30.FY 2014 revenue of $345 mln - Thomson Reuters I/B/E/S.  Full Article

Accuray Inc 's CyberKnife M6 system receives shonin approval
Thursday, 27 Mar 2014 08:35am EDT 

Accuray Inc:Received Shonin approval from Japanese Ministry of Health, Labor and Welfare (MHLW) to market CyberKnife M6.CyberKnife is a System to treat radiation therapy patients.CyberKnife System enables physicians to precisely maximize dose, minimize side effects and maximize patient comfort.Patients treated with the CyberKnife System will not experience the discomfort of breath-holding, abdominal compression, breathing apparatus, or metal head-frames typically associated with other radiation therapy devices.  Full Article

Accuray Inc raises FY 2014 revenue guidance
Thursday, 30 Jan 2014 04:02pm EST 

Accuray Inc:Now sees FY 2014 total revenue at a range of $340 million to $350 million.This compares to the previous financial guidance of total revenue in the range of $325 million to $345 million which was provided on Aug. 27, 2013 and reaffirmed on Nov. 7, 2013.FY 2014 revenue of $333 mln - Thomson Reuters I/B/E/S.  Full Article

BRIEF-Scandidos sells Delta4 Phantom to Accuray

* Says has been selected by Accuray as supplier of measurement system Delta4 Phantom Source text: http://bit.ly/1BLhTTx Further company coverage: (Gdynia Newsroom)

Search Stocks